Home » Business News » 2011 » March » March 29, 2011

Axelar's AXL1717 to Be Presented at the American Association of Cancer Research (AACR) 102nd Annual Meeting in Orlando, Florida

March 29, 2011 - Stockholm, Sweden

Axelar AB today announced that studyresults from the Phase I study evaluating AXL1717 for the treatment ofsquamouscell lung carcinoma will be presented at the American Association of CancerResearch annual meeting being held in Orlando, Florida. Axelar is part oftheKarolinska Development portfolio of companies.

Poster presentation (abstract # 1276): "A novel targeted oral Insulin-likeGrowth Factor 1 (IGF-1) receptor inhibitor and its implications forpatientswith squamous cell lung carcinoma."

* Monday April 4, 2011 from 8:00 a.m. - 12:00 p.m.
* General poster session in exhibit hall A4-C, poster section 12.
* Abstract number 1276
* Lead author: Ekman, S.


About Axelar

Axelar AB is a Swedish biotech company founded in 2003. The company isdeveloping insulin-like growth factor-1 (IGF-1) receptor inhibitors fortreatment of cancer and other diseases. Axelar is part of the KarolinskaDevelopment portfolio of

About AXL1717

Axelar's lead compound, AXL1717 provides a novel treatment regimen for awiderange of cancers. AXL1717 is the first targeted oral small-molecule IGF-1receptor inhibitor with no effect on the insulin receptor. AXL1717 ispresentlyundergoing phase I/II clinical trials and the compound combines a superiorpreclinical efficacy against numerous tumors with an excellent tolerabilityprofile. Most tumor cells are dependent on the IGF-1 receptor signalpathway andthe IGF-1 receptor is therefore regarded as a very promising target forcancertherapy. To date, there are no IGF-1 receptor inhibitor drugs on themarket.

News Release as PDF:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright andother applicable laws; and

(ii) they are solely responsible for the content, accuracy andoriginality of the information contained therein.

Source: Axelar AB via Thomson Reuters ONE


For further information, please contact:
Fredrik Rook
VP Business Development
Axelar AB
Phone: +46 (0) 708 67 60 38
e-mail: Email Contact


Comment on this story